Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger)

Clinical Trial ID NCT00842634

PubWeight™ 114.69‹?›

🔗 Visit the page for NCT00842634

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010 18.88
2 ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013 11.58
3 High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013 8.40
4 A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 2011 7.93
5 Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014 7.64
6 Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 2011 6.90
7 Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009 3.06
8 Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015 2.56
9 Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013 2.11
10 Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 2012 2.02
11 Advances in targeted genome editing. Curr Opin Chem Biol 2012 1.97
12 Prospects for treatment of latent HIV. Clin Pharmacol Ther 2012 1.91
13 Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011 1.50
14 HIV-1 transcription and latency: an update. Retrovirology 2013 1.49
15 Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 2013 1.48
16 Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev 2013 1.41
17 Developing strategies for HIV-1 eradication. Trends Immunol 2012 1.38
18 Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One 2014 1.24
19 Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS 2011 1.22
20 Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 2013 1.14
21 Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum Gene Ther 2011 1.11
22 Targeted gene disruption to cure HIV. Curr Opin HIV AIDS 2013 1.09
23 Newer gene editing technologies toward HIV gene therapy. Viruses 2013 1.07
24 Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med 2012 1.07
25 Gene correction by homologous recombination with zinc finger nucleases in primary cells from a mouse model of a generic recessive genetic disease. Mol Ther 2010 1.04
26 Novel approaches to inhibit HIV entry. Viruses 2012 1.00
27 T-cell therapies for HIV. Immunotherapy 2013 0.99
28 Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9. Mol Cells 2015 0.97
29 Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res 2014 0.95
30 Creating genetic resistance to HIV. Curr Opin Immunol 2012 0.93
31 A cure for AIDS: a matter of timing? Retrovirology 2013 0.92
32 Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol 2013 0.92
33 Eradication of HIV and Cure of AIDS, Now and How? Front Immunol 2013 0.92
34 Native homing endonucleases can target conserved genes in humans and in animal models. Nucleic Acids Res 2011 0.90
35 Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol 2014 0.86
36 CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy 2013 0.85
37 Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016 0.85
38 Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) 2014 0.84
39 HIV-1 functional cure: will the dream come true? BMC Med 2015 0.84
40 State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med 2014 0.84
41 Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation. Mol Ther Nucleic Acids 2013 0.84
42 RNA interference approaches for treatment of HIV-1 infection. Genome Med 2015 0.81
43 Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther 2015 0.81
44 Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses 2013 0.80
45 Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery. Sci Rep 2014 0.79
46 Zinc Finger Nucleases: Tailor-made for Gene Therapy. Drugs Future 2012 0.79
47 The clinical applications of genome editing in HIV. Blood 2016 0.79
48 Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system. Mol Ther Methods Clin Dev 2014 0.79
49 Gene therapy targeting HIV entry. Viruses 2014 0.79
50 Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells Cloning 2015 0.78
51 Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev 2016 0.78
52 Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev 2016 0.77
53 TALENs targeting HBV: designer endonuclease therapies for viral infections. Mol Ther 2013 0.76
54 In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci 2016 0.75
55 From hacking the human genome to editing organs. Organogenesis 2015 0.75
56 T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy 2016 0.75
57 Advances in homology directed genetic engineering of human pluripotent and adult stem cells. World J Stem Cells 2013 0.75
58 Bone marrow transplant muffles HIV. Nat Med 2009 0.75
Next 100